Modern methodologies and tools for human hazard assessment of chemicals

EFSA Journal

Volumn 12, Issue 4, 2014, Pages

[No Author Info available]

Author keywords

adverse outcome pathway; in silico; integrated testing strategy; mode of action; OMICs; physiologically based models

Indexed keywords

EID: 84983804101     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2014.3638     Document Type: Review

References (310)

1. Abass KM, 2013. From in vitro hepatic metabolic studies towards human health risk assessment: Two case studies of diuron and carbosulfan. Pesticide Biochemistry and Physiology, 107, 258–265.
2. Aliferis KA and Jabaji S, 2011. Metabolomics - A robust bioanalytical approach for the discovery of the modes-of-action of pesticides: A review. Pesticide Biochemistry and Physiology, 100, 105–117.
3. Alqahtani S, Mohamed LA and Kaddoumi A, 2013. Experimental models for predicting drug absorption and metabolism. Expert Opinion on Drug Metabolism and Toxicology, 9, 1241–1254.
4. Allen BC, Hack CE and Clewell HJ, 2007. Use of Markov chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age. Risk Analysis, 27, 947–959.
5. Al-Subeihi AA, Spenkelink B, Rachmawati N, Boersma MG, Punt A and Vervoort J, 2011. Physiologically based biokinetic model of bioactivation and detoxification of the alkenylbenzene methyleugenol in rat. Toxicology in Vitro, 25, 267–285.
6. Alyea RA, Gollapudi BB and Rasoulpour RJ, 2014. Are we ready to consider transgenerational epigenetic effects in human health risk assessment? Environmental and Molecular Mutagenesis, 55, 292–298.
7. Amacher DE, 2010. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicology and Applied Pharmacology, 245, 134–142.
8. Amzal B, Julin B, Vahter M, Wolk A, Johanson G and Akesson A, 2009. Population toxicokinetic modeling of cadmium for health risk assessment. Environmental Health Perspectives, 117, 1293–1301.
9. Andersen V, Halfvarson J and Vogel U, 2012. Colorectal cancer in patients with inflammatory bowel disease: can we predict risk? World Journal of Gastroenterology, 18, 4091–4094.
10. Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, Mount DR, Nichols JW, Russom CL, Schmieder PK, Serrrano JA, Tietge JE and Villeneuve DL, 2010. Adverse Outcome Pathways: A Conceptual Framework to Support Ecotoxicology Research and Risk Assessment. Environmental Toxicology and Chemistry, 29, 730–741.
11. Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, Thanacoody RH, Gray AJ, Webb DJ, Moggs JG, Bateman DN, Goldring CE and Park BK, 2013. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology, 58, 777–787.
12. Anway MD, Cupp AS, Uzumcu M and Skinner MK, 2005. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science, 308, 1466–1469.
13. Attene-Ramos MS, Miller N, Huang RL, Michael S, Itkin M, Kavlock RJ, Austin CP, Shinn P, Simeonov A, Tice RR and Xia MH, 2013. The Tox21 robotic platform for the assessment of environmental chemicals - from vision to reality. Drug Discovery Today, 18, 716–723.
14. Aylward LL, Krishnan K, Kirman CR, Nong A and Hays SM, 2011. Biomonitoring equivalents for deltamethrin. Regulatory Toxicology and Pharmacology, 60, 189–199.
15. Bartels M, Rick D, Lowe E, Loizou G, Price P, Spendiff M, Arnold S, Cocker J and Ball N, 2012. Development of PK- and PBPK-based modeling tools for derivation of biomonitoring guidance values. Computer Methods and Programs in Biomedicine, 108, 773–788.
16. Basketter DA, 2012. Non-animal approaches in skin toxicology. Archives in Toxicology, 86, 1159–1160.
17. Benfenati E, Benigni R, Demarini DM, Helma C, Kirkland D, Martin TM, Mazzatorta G, Ouedraogo-Arras G, Richard AM, Schilter B, Schoonen WGEJ, Snyder RD and Yang C, 2009. Predictive Models for Carcinogenicity and Mutagenicity: Frameworks, State-of-the-Art, and Perspectives. Journal of Environmental Science and Health Part C, 27, 2, 57–90.
18. Berger B, Peng J and Singh M, 2013. Computational solutions for omics data. Nature Review Genetics, 14, 333–346.
19. Bernillon Pand Bois FY, 2000. Statistical issues in toxicokinetic modeling: A Bayesian perspective. Environmental Health Perspectives, 108, 883–893.
20. Blaauboer BJ, 2010. Biokinetic Modeling and in Vitro-in Vivo Extrapolations. Journal of Toxicology and Environmental Health-Part B-Critical Reviews, 13, 242–252.
21. Blackburn K, Bjerke D, Daston G, Felter S, Mahony C, Naciff J, Robison S and Wu SD, 2011. Case studies to test: A framework for using structural, reactivity, metabolic and physicochemical similarity to evaluate the suitability of analogs for SAR-based toxicological assessments. Regulatory Toxicology and Pharmacology, 60, 120–135.
22. Boccard J, Veuthey JL and Rudaz S, 2010. Knowledge discovery in metabolomics: An overview of MS data handling. Journal of Separation Science, 33, 290–304.
23. Bois FY, Jamei M and Clewell HJ, 2010. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology, 278, 256–267.
24. Boitier E, Amberg A, Barbie V, Blichenberg A, Brandenburg A, Gmuender H, Gruhler A, McCarthy D, Meyer K, Riefke B, Raschke M, Schoonen W, Sieber M, Suter L, Thomas CE and Sajot N, 2011. A comparative integrated transcript analysis and functional characterization of differential mechanisms for induction of liver hypertrophy in the rat. Toxicology and Applied Pharmacology, 252, 85–96.
25. Boobis AR, 2005. A tiered approach to assessing the toxicology of pesticides. Toxicology Letters, 158, S30–S31.
26. Boobis AR, Cohen SM, Dellarco V, McGregor D, Vickers C, Willcocks D and Farland W, 2006. IPCS framework for analysing the relevance of a cancer mode of action for humans. Toxicology Letters, 164, S254–S255.
27. Boobis AR, Doe JE, Heinrich-Hirsch B, Meek ME, Munn S, Ruchirawat M, Schlatter J, Seed J and Vickers C, 2008. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Critical Reviews in Toxicology, 38, 87–96.
28. Bouhifd M, Hartung T, Hogberg HT, Kleensang A and Zhao L, 2013. Review: Toxicometabolomics. Journal of Applied Toxicology, 33, 1365–1383.
29. Bueters T, Juric S, Sohlenius-Sternbeck AK, Hu Y and Bylund J, 2013. Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human. Xenobiotica, 43, 607–616.
30. Bow DAJ, Perry JL, Simon JD and Pritchard JB, 2006. The impact of plasma protein binding on the renal transport of organic anions. Journal of Pharmacology and Experimental Therapeutics, 316, 349–355.
31. Burgess-Herbert SL and Euling SY, 2013. Use of comparative genomics approaches to characterize interspecies differences in response to environmental chemicals: challenges, opportunities, and research needs. Toxicology and Applied Pharmacology, 15;271, 372-385.
32. Caldwell JC, Evans MV and Krishnan K, 2012. Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms. Journal of Toxicology, 2012, 852384.
33. Cecconi D and Zamo A, 2011. Proteomics of human cancer tissues and cells. Trac-Trends in Analytical Chemistry, 30, 346–359.
34. Chadeau-Hyam M, Campanella G, Jombart T, Bottolo L, Portengen L, Vineis P, Liquet B and Vermeulen RC, 2013. Deciphering the complex: methodological overview of statistical models to derive OMICS-based biomarkers. Environmental and Molecular Mutagenesis, 54, 542–557.
35. *2, affect phenytoin autoinduction of clearance and maintenance dose. Journal of Pharmacology and Experimental Therapeutics, 332, 599–611.
36. Cheng S and Bois FY, 2011. A Mechanistic Modeling Framework for Predicting Metabolic Interactions in Complex Mixtures. Environmental Health Perspectives, 119, 1712–1718.
37. Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, Lee PW and Tang Y, 2013. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. Journal of Chemical Information and Modeling, 52, 3099–3105.
38. Chen Y, Liu L, Monshouwer M and Fretland AJ, 2011. Determination of timedependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions. Drug Metabolism and Disposition, 39, 2085–2092.
39. Chiu WA and Bois FY, 2006. Revisiting the population toxicokinetics of tetrachloroethylene. Archives of Toxicology, 80, 382–385.
40. Choi K, Pfund WP, Andersen ME, Thomas RS, Clewell HJ and Lecluyse EL, 2013. Development of 3D Dynamic Flow Model of Human Liver and its Application to Prediction of Metabolic Clearance of 7-Ethoxycoumarin. Tissue Engineering. Part C Methods, doi: 10.1089/ten.TEC.2013.0562
41. Clewell HJ, Crump KS, Gentry PR and Shipp AM, 2000. Site-specific reference dose for methylmercury for fish-eating populations. Fuel Processing Technology, 65, 43–54.
42. Clewell HJ, Gentry PR, Covington TR, Sarangapani R and Teeguarden JG, 2004. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicological Sciences, 79, 381–393.
43. Clewell RA and Clewell HJ, 2008. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regulatory Toxicology and Pharmacology, 50, 129–143.
44. Coecke S, Ahr H, Blaauboer BJ, Bremer S, Casati S, Castell J, Combes R, Corvi R, Crespi CL, Cunningham ML, Elaut G, Eletti B, Freidig A, Gennari A, Ghersi-Egea JF, Guillouzo A, Hartung T, Hoet P, Ingelman-Sundberg M, Munn S, Janssens W, Ladstetter B, Leahy D, Long A, Meneguz A, Monshouwer M, Morath S, Nagelkerke F, Pelkonen O, Ponti J, Prieto P, Richert L, Sabbioni E, Schaack B, Steiling W, Testai E, Vericat JA and Worth A, 2006. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Alternatives to Laboratory Animals, 34, 49–84.
45. Coecke S, Pelkonen O, Leite SB, Bernauer U, Bessems JGM, Bois FY, Gundert-Remy U, Loizou G, Testai E and Zaldivar JM, 2013. Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. Toxicology in Vitro, 27, 1570–1577.
46. Collins BC, Miller CA, Sposny A, Hewitt P, Wells M, Gallagher WM and Pennington SR, 2012. Development of a Pharmaceutical Hepatotoxicity Biomarker Panel Using a Discovery to Targeted Proteomics Approach. Molecular & Cellular Proteomics, 11, 394–410.
47. Com E, Boitier E, Marchandeau JP, Brandenburg A, Schroeder S, Hoffmann D, Mally A and Gautier JC, 2012. Integrated transcriptomic and proteomic evaluation of gentamicin nephrotoxicity in rats. Toxicology and Applied Pharmacology, 258, 124–133.
48. Conolly RB, Gaylor DW and Lutz WK, 2005. Population variability in biological adaptive responses to DNA damage and the shapes of carcinogen dose-response curves. Toxicology and Applied Pharmacology, 207, 570–575.
49. Covington TR, Gentry PR, Van Landingham CB, Andersen ME, Kester JE and Clewell HJ, 2007. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regulatory Toxicology and Pharmacology, 47, 1–18.
50. Crowell SR, Henderson WM, Kenneke JF and Fisher JW, 2011. Development and application of a physiologically based pharmacokinetic model for triadimefon and its metabolite triadimenol in rats and humans. Toxicology Letters, 205, 154–162.
51. Crump KS, Chen C, Chiu WA, Louis TA, Portier CJ, Subramaniam RP and White PD, 2010. What Role for Biologically Based Dose-Response Models in Estimating Low-Dose Risk? Environmental Health Perspectives, 118, 585–588.
52. Darwich AS, Neuhoff S, Jamei M and Rostami-Hodjegan A, 2010. Interplay of metabolism and transport in determining oral drug absorption and “gut wall metabolism: a simulation assessment using” he “Advanced Dissolution, Absorption, Metabolism (ADAM)” model. Current Drug Metabolism, 11, 716–729.
53. David RM, Clewell HJ, Gentry PR, Covington TR, Morgott DA and Marino DJ, 2006. Revised assessment of cancer risk to dichloromethane - II. Application of probabilistic methods to cancer risk determinations. Regulatory Toxicology and Pharmacology, 45, 55–65.
54. Davies MN, Meaburn EL and Schalkwyk LC, 2010. Gene set enrichment; a problem of pathways. Brief Functional Genomics, 9, 385–390.
55. Dennison JE, Andersen ME and Yang RSH, 2003. Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. Inhalation Toxicology, 15, 961–986.
56. DeWoskin RS, Barone S, Clewell HJ and Setzer RW, 2001. Improving the development and use of biologically based dose response models (BBDR) in risk assessment. Human and Ecological Risk Assessment, 7, 1091–1120.
57. Doerge DR, Twaddle NC, Woodling KA and Fisher JW, 2010. Pharmacokinetics of bisphenol A in neonatal and adult rhesus monkeys. Toxicology and Applied Pharmacology, 248, 1–11.
58. Doerge DR, Young JF, Chen JJ, DiNovi MJ and Henry SH, 2008. Using dietary exposure and physiologically based pharmacokinetic/pharmacodynamic modeling in human risk extrapolations for acrylamide toxicity. Journal of Agricultural and Food Chemistry, 56, 6031–6038.
59. Döring B and Petzinger E, 2014. Phase 0 and phase III transport in various organs: Combined concept of phases in xenobiotic transport and metabolism. Drug Metabolism Reviews, PMID:24483608.
60. Dorne JL, 2010. Metabolism, variability and risk assessment. Toxicology, 268, 156–164.
61. Dorne JL, Amzal B, Bois F, Crepet A, Tressou J and Verger P, 2012. Population effects and variability. Methods in the Molecular Biology, 929, 521–581.
62. Draghici S, Kulaeva O, Hoff B, Petrov A, Shams S and Tainsky MA, 2013. Noise sampling method: an ANOVA approach allowing robust selection of differentially regulated genes measured by DNA microarrays. Bioinformatics, 19, 1348–1359.
63. Du LF, Wang H, Xu W, Zeng Y, Hou YR, Zhang YQ, Zhao XJ and Sun CH, 2013. Application of Ultraperformance Liquid Chromatography/Mass Spectrometry-Based Metabonomic Techniques to Analyze the Joint Toxic Action of Long-term Low-Level Exposure to a Mixture of Organophosphate Pesticides on Rat Urine Profile. Toxicological Sciences, 134, 195–206.
64. ECHA (European Chemicals Agency), 2008. REACH Guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals. Available online: echa.europa.eu/documents/10162/13632/information_requirements_r6_en.pdf
65. EFSA (European Food Safety Authority), 2005. Opinion of the Scientific Committee on a request from EFSA related to A Harmonised Approach for Risk Assessment of Substances which are both Genotoxic and Carcinogenic. The EFSA Journal 2005, 282, 1–31.
66. EFSA (European Food Safety Authority), 2008. Scientific Opinion of the Panel on Plant Protection Products and their Residues (PPR Panel) on a request from the EFSA evaluate the suitability of existing methodologies and, if appropriate, the identification of new approaches to assess cumulative and synergistic risks from pesticides to human health with a view to set MRLs for those pesticides in the frame of Regulation (EC) 396/2005. The EFSA Journal 2008, 705, 1–84. doi:10.2903/j.efsa.2008.705
67. EFSA (European Food Safety Authority), 2009a. Use of the benchmark dose approach in risk assessment. Guidance of the Scientific Committee. The EFSA Journal 2009, 1150, 1–72.
68. EFSA (European Food Safety Authority), 2009b. Scientific Opinion of the Panel on Contaminants in the Food Chain on a request from the European Commission on cadmium in food. The EFSA Journal 2009, 980, 1–139.
69. EFSA (European Food Safety Authority), 2009c. Technical report of EFSA prepared by Assessment Methodology Unit on Meta-analysis of Dose-Effect Relationship of Cadmium for Benchmark Dose Evaluation. The EFSA Journal 2009, 254r, 1–62.
70. EFSA (European Food Safety Authority), 2009d. Scientific opinion on the re-evaluation of Allura Red AC (E 129) as a food additive on request from the European Commission. The EFSA Journal 2009, 7(11):1327, 39 pp. doi:10.2903/j.efsa.2009.1327
71. EFSA (European Food Safety Authority), 2013. International Framework Dealing with Human Risk Assessment of Combined Exposure to Multiple Chemicals. EFSA Journal 2013;11(7):3313, 69 pp. doi:10.2903/j.efsa.2013.3313
72. EFSA (European Food Safety Authority), 2014a. A systematic procedure for the identification of emerging chemical risks in the food and feed chain. EFSA supporting publication 2014:EN-547. 40 pp.
73. EFSA (European Food Safety Authority), 2014b. Towards an integrated environmental risk assessment of multiple stressors on bees: review of research projects in Europe, knowledge gaps and recommendations. EFSA Journal 2014;12(3):3594, 102 pp. doi:10.2903/j.efsa.2014.3594
74. EFSA ANS Panel (EFSA Panel on Food Additives and Nutrient Sources Added to Food), 2013. Statement on Allura Red AC and other sulphonated mono azodyesauthorised as food and feed additives. EFSA Journal 2013;11(6):3234, 25 pp. doi:10.2903/j.efsa.2013.3234
75. EFSA PPR Panel (EFSA Panel on Plant Protection Products and their Residues), 2012. Scientific Opinion on evaluation of the toxicological relevance of pesticide metabolites for dietary risk assessment. EFSA Journal 2012;10(07):2799, 187 pp. doi:10.2903/j.efsa.2012.2799
76. EFSA SC (EFSA Scientific Committee), 2012. Scientific Opinion on exploring options for providing advice about possible human health risks based on the concept of Threshold of Toxicological Concern (TTC). EFSA Journal 2012;10(7):2750, 103 pp. doi:10.2903/j.efsa.2012.2750
77. Ellinger-Ziegelbauer H, Adler M, Amberg A, Brandenburg A, Callanan JJ, Connor S, Fountoulakis M, Gmuender H, Gruhler A, Hewitt P, Hodson M, Matheis KA, McCarthy D, Raschke M, Riefke B, Schmitt CS, Sieber M, Sposny A, Suter L, Sweatman B and Mally A, 2011. The enhanced value of combining conventional and “omics” analyses in early assessment of drug-induced hepatobiliary injury. Toxicology and Applied Pharmacology, 252, 97–111.
78. Enoch SJ, Roberts DW and Cronin MT, 2010. Mechanistic category formation for the prediction of respiratory sensitization. Chemical Research in Toxicology, 23, 1547–1555.
79. Eustache F, Mondon F, Canivenc-Lavier MC, Lesaffre C, Fulla Y, Berges R, Cravedi JP, Vaiman D and Auger J, 2009. Chronic dietary exposure to a low-dose mixture of genistein and vinclozolin modifies the reproductive axis, testis transcriptome, and fertility. Environmental Health Perspectives, 117, 1272–1279.
80. Faller LD, 2008. Mechanistic studies of sodium pump. Archives of Biochemistry and Biophysics, 476, 12–21.
81. Fan JH, Chen S, Chow ECY and Pang KS, 2010. PBPK Modeling of Intestinal and Liver Enzymes and Transporters in Drug Absorption and Sequential Metabolism. Current Drug Metabolism, 11, 743–761.
82. Feng Z, Sun X, Yang J, Hao D, Du L, Wang H, Xu W, Zhao X and Sun C, 2012. Metabonomics analysis of urine and plasma from rats given long-term and low-dose dimethoate by ultraperformance liquid chromatography-mass spectrometry. Chemico-Biological Interactions, 199, 143–153.
83. Fiehn O, Robertson D, Griffin J, van der Werf M, Nikolau B, Morrison N, Sumner LW, Goodacre R, Hardy NW, Taylor C, Fostel J, Kristal B, Kaddurah-Daouk R, Mendes P, van Ommen B, Lindon JC and Sansone SA, 2007. The metabolomics standards initiative (MSI). Metabolomics, 3, 175–178.
84. Fisher JW, Twaddle NC, Vanlandingham M and Doerge DR, 2011. Pharmacokinetic modeling: Prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans. Toxicology and Applied Pharmacology, 257, 122–136.
85. Forgacs AL, Dere E, Angrish MM and Zacharewski TR, 2013. Comparative analysis of temporal and dose-dependent TCDD-elicited gene expression in human, mouse, and rat primary hepatocytes. Toxicological Sciences, 133, 54–66.
86. Fountoulakis M, Berndt P, Boelsterli UA, Crameri F, Winter M, Albertini S and Suter L, 2000. Two-dimensional database of mouse liver proteins: Changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis, 21, 2148–2161.
87. Gangwal S, Reif DM, Mosher S, Egeghy PP, Wambaugh JF, Judson RS and Hubal EAC, 2012. Incorporating exposure information into the toxicological prioritization index decision support framework. Science of the Total Environment, 435–436, 316-325.
88. Gentry PR, Hack CE, Haber L, Maier A and Clewell HJ, 2002. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: Examples with warfarin and parathion. Toxicological Sciences, 70, 120–139.
89. Gerlowski LE and Jain RK, 1983. Physiologically Based Pharmacokinetic Modeling - Principles and Applications. Journal of Pharmacological Sciences, 72, 1103–1127.
90. Gissi A, Gadaleta D, Floris M, Olla S, Carotti A, Novellino E, Benfenati E and Nicolotti O, 2014. An alternative QSAR-based approach for predicting the bioconcentration factor for regulatory purposes. ALTEX, 31, 23–36.
91. Goldstone JV, McArthur AG, Kubota A, Zanette J, Parente T, Jonsson ME, Nelson DR and Stegeman JJ, 2010. Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish. BMC Genomics, 11, 643–663.
92. Goodman JE, Boyce CP, Pizzurro DM and Rhomberg LR, 2014. Strengthening the foundation of next generation risk assessment. Regulatory Toxicology and Pharmacology, 68, 160–170.
93. Govarts E, Nieuwenhuijsen M, Schoeters G, Ballester F, Bloemen K, de Boer M, Chevrier C, Eggesbo M, Guxens M, Kramer U, Legler J, Martinez D, Palkovicova L, Patelarou E, Ranft U, Rautio A, Petersen MS, Slama R, Stigum H, Toft G, Trnovec T, Vandentorren S, Weihe P, Kuperus NW, Wilhelm M, Wittsiepe J, Bonde JP and Eneieco O, 2012. Birth Weight and Prenatal Exposure to Polychlorinated Biphenyls (PCBs) and Dichlorodiphenyldichloroethylene (DDE): A Meta-analysis within 12 European Birth Cohorts. Environmental Health Perspectives, 120, 162–170.
94. Groothuis GMM and de Graaf IAM, 2013. Precision-cut Intestinal Slices as In Vitro Tool for Studies on Drug Metabolism. Current Drug Metabolism, 14, 112–119.
95. Haddad S, Beliveau M, Tardif R and Krishnan K, 2001. A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. Toxicological Sciences, 63, 125–131.
96. Haddad S, Tardif G and Krishnan K, 1999. Physiological modeling of the toxicokinetic interactions in a quaternary mixture of aromatic hydrocarbons. Toxicology and Applied Pharmacology, 161, 249–257.
97. Haug K, Salek RM, Conesa P, Hastings J, de Matos P, Rijnbeek M, Mahendraker T, Williams M, Neumann S, Rocca-Serra P, Maguire E, Gonzalez-Beltran A, Sansone SA, Griffin JL and Steinbeck C, 2013. MetaboLights-an open-access general-purpose repository for metabolomics studies and associated meta-data. Nucleic Acids Research, 41, D781–786.
98. Herrero M, Simo C, Garcia-Canas V, Ibanez E and Cifuentes A, 2012. Foodomics: MS-based strategies in modern food science and nutrition. Mass Spectrometry Reviews, 31, 49–69.
99. Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L and Consortium IT, 2013. Emerging Transporters of Clinical Importance: An Update from the International Transporter Consortium. Clinical Pharmacology & Therapeutics, 94, 52–63.
100. Hinderliter PM, Price PS, Bartels MJ, Timchalk C and Poet TS, 2011. Development of a source-to-outcome model for dietary exposures to insecticide residues: An example using chlorpyrifos. Regulatory Toxicology and Pharmacology, 61, 82–92.
101. Hood L, 2012. Tackling the Microbiome. Science, 336(6086), 1209.
102. IEH (Institute of Environment and Health), 2013. Predictive approaches to chemical hazard identification and characterisation: current use by UK government departments and agencies. Institute of Environment and Health, Cranfield University, UK. Available online: ieh.cranfield.ac.uk/ighrc/pdf/cr%20reports/cr161.pdf
103. Illig T, Gieger C, Zhai G, Romisch-Margl W, Wang-Sattler R, Prehn C, Altmaier E, Kastenmuller G, Kato BS, Mewes HW, Meitinger T, de Angelis MH, Kronenberg F, Soranzo N, Wichmann HE, Spector TD, Adamski J and Suhre K, 2010. A genome-wide perspective of genetic variation in human metabolism. Nature Genetics, 42, 137–141.
104. Ishii M, Toda T, Ikarashi N, Ochiai W and Sugiyama K, 2012. Effects of Intestinal Flora on the Expression of Cytochrome P450 3A in the Liver. Yakugaku Zasshi, 132, 301–310.
105. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G and Rostami-Hodjegan A, 2009. The Simcyp population-based ADME simulator. Expert Opinion on Drug Metabolism & Toxicology, 5, 211–223.
106. Jayaraman R, Pilla Reddy V, Pasha MK, Wang H, Sangthongpitag K, Yeo P, Hu CY, Wu X, Xin L, Goh E, New LS and Ethirajulu K, 2011. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metabolism and Disposition, 39, 2219–2232.
107. Jongeneelen FJ and Berge WF, 2011. A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results. Annals of Occupational Hygiene, 55, 841–864.
108. Jourdan F, Cottret L, Huc L, Wildridge D, Scheltema R, Hillenweck A, Barrett MP, Zalko D, Watson DG and Debrauwer L, 2010. Use of reconstituted metabolic networks to assist in metabolomic data visualization and mining. Metabolomics, 6, 312–321.
109. JRC (Joint Research Centre), 2010. Scientific Report submitted to EFSA. Applicability of QSAR analysis to the evaluation of the toxicological relevance of metabolites and degradates of pesticide active substances for dietary risk assessment. Prepared by Computational Toxicology Group, Institute for Health & Consumer Protection, European Commission-Joint Research Centre, Ispra, Italy (Question No EFSA-Q-2009-01076. Accepted for Publication on 5 May 2010).
110. JRC (Joint Research Centre), 2011. Applicability of QSAR analysis in the evaluation of developmental and neurotoxicity effects for the assessment of the toxicological relevance of metabolites and degradates of pesticide active substances for dietary risk assessment. Report produced for EFSA. Available online: www.efsa.europa.eu/en/supporting/pub/169e.htm
111. Kamp H, Fabian E, Groeters S, Herold M, Krennrich G, Looser R, Mattes W, Mellert W, Prokoudine A, Ruiz-Noppinger P, Strauss V, Walk T, Wiemer J and van Ravenzwaay B, 2012. Application of in vivo metabolomics to preclinical/toxicological studies: case study on phenytoin-induced systemic toxicity. Bioanalysis, 4, 2291–2301.
112. Keane TM, Goodstadt L, Danecek P, White MA, Wong K, Yalcin B, Heger A, Agam A, Slater G, Goodson M, Furlotte NA, Eskin E, Nellaker C, Whitley H, Cleak J, Janowitz D, Hernandez-Pliego P, Edwards A, Belgard TG, Oliver PL, McIntyre RE, Bhomra A, Nicod J, Gan X, Yuan W, van der Weyden L, Steward CA, Bala S, Stalker J, Mott R, Durbin R, Jackson IJ, Czechanski A, Guerra-Assuncao JA, Donahue LR, Reinholdt LG, Payseur BA, Ponting CP, Birney E, Flint J and Adams DJ, 2011. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature, 477, 289–294.
113. Kim TH, Ahn MY, Lim HJ, Lee YJ, Shin YJ, De U, Lee J, Lee BM, Kim S and Kim HS, 2012. Evaluation of metabolomic profiling against renal toxicity in Sprague-Dawley rats treated with melamine and cyanuric acid. Archives of Toxicology, 86, 1885–1897.
114. Kleinstreuer NC, Smith AM, West PR, Conard KR, Fontaine BR, Weir-Hauptman AM, Palmer JA, Knudsen TB, Dix DJ, Donley ELR and Cezar GG, 2011. Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. Toxicology and Applied Pharmacology, 257, 111–121.
115. Knaak JB, Dary CC, Power F, Thompson CB and Blancato JN, 2004. Physicochemical and biological data for the development of predictive organophosphorus pesticide QSARs and PBPK/PD models for human risk assessment. Critical Reviews in Toxicology, 34, 143–207.
116. Knaak JB, Dary CC, Okino MS, Power FW, Zhang X, Thompson CB, Tornero-Velez R and Blancato JN, 2008. Parameters for Carbamate Pesticide QSAR and PBPK/PD Models for Human Risk Assessment. Review of Environmental Contaminants in Toxicology, 193, 53–212.
117. Knudsen AD, Bennike T, Kjeldal H, Birkelund S, Otzen DE and Stensballe A, 2014. Condenser: A statistical aggregation tool for multi-sample quantitative proteomic data from Matrix Science Mascot Distiller. Journal of Proteomics. doi: 10.1016/j.jprot.2014.02.001
118. Kopec AK, Boverhof DR, Nault R, Harkema JR, Tashiro C, Potter D, Sharratt B, Chittim B and Zacharewski TR, 2013. Toxicogenomic evaluation of long-term hepatic effects of TCDD in immature, ovariectomized C57BL/6 mice. Toxicological Sciences, 135, 465–475.
119. Kobayashi CA, Leite Ade L, da Silva TL, dos Santos LD, Nogueira FC, Santos KS, de Oliveira RC, Palma MS, Domont GB and Buzalaf MA, 2011. Proteomic analysis of urine in rats chronically exposed to fluoride. Journal of Biochemical and Molecular Toxicology, 25, 8–14.
120. Koen YM, Gogichaeva NV, Alterman MA and Hanzlik RP, 2007. A proteomic analysis of bromobenzene reactive metabolite targets in rat liver cytosol in vivo. Chemical Research in Toxicology, 20, 511–519.
121. Koulman A, Lane GA, Harrison SJ and Volmer DA, 2009. From differentiating metabolites to biomarkers. Analytical and Bioanalytical Chemistry, 394, 663–670.
122. Krewski D, Westphal M, Al-Zoughool M, Croteau MC and Andersen ME, 2011. New Directions in Toxicity Testing. Annual Review of Public Health, 32, 161–178.
123. Kroes R, Renwick AG, Cheeseman M, Kleiner J, Mangelsdorf I, Piersma A, Schilter B, Schlatter J, van Schothorst F, Vos JG and Wurtzen G, 2004. Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food and Chemical Toxicology, 42, 65–83.
124. Kroes R, Kleiner J and Renwick A, 2005. The threshold of toxicological concern concept in risk assessment. Toxicological Sciences, 86, 226–230.
125. Kumar V, Schuck EL, Pelletier RD, Farah N, Condon KB, Ye M, Rowbottom C, King BM, Zhang ZY, Saxton PL, Wong YN, 2011. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species. Cancer Chemotherapy and Pharmacology, 69, 229–237.
126. Kusuhara H and Sugiyama Y, 2009. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metabolism and Pharmacokinetics, 24, 37–52.
127. Lafond M, Bouza B, Eyrichine S, Bonnin E, Crost EH, Geraert PA, Giardina T and Ajandouz el H, 2011. An integrative in vitro approach to analyse digestion of wheat polysaccharides and the effect of enzyme supplementation. British Journal of Nutrition, 106, 264–273.
128. Lan K, Xie GX and Jia W, 2013. Towards Polypharmacokinetics: Pharmacokinetics of Multicomponent Drugs and Herbal Medicines Using a Metabolomics Approach. Evidence-Based Complementary and Alternative Medicine. doi: 10.1155/2013/819147
129. Lapenna S and Worth A, 2011. Analysis of the Cramer classification scheme for oral systemic toxicity - implications for its implementation in Toxtree. JRC Scientific and Technical Report EUR 24898 EN. Publications Office of the European Union, Luxembourg. Available from: publications.jrc.ec.europa.eu/repository/
130. Law FC and Wang Y, 1997. [A review of physiologically based pharmacokinetic models: development and applications]. Yao Xue Xue Bao, 32, 151–160.
131. Lee MY, Dordick JS and Clark DS, 2010a. Metabolic enzyme microarray coupled with miniaturized cell-culture array technology for high-throughput toxicity screening. Methods in Molecular Biology, 632, 221–237.
132. Lee S, Poet TS, Smith JN, Busby-Hjerpe AL and Timchalk C, 2010b. Effect of in vivo nicotine exposure on chlorpyrifos pharmacokinetics and pharmacodynamics in rats. Chemico-Biological Interactions, 184, 449–457.
133. Lee S, Poet TS, Smith JN, Hjerpe AL, Gunawan R and Timchalk C, 2011. Impact of repeated nicotine and alcohol coexposure on in vitro and in vivo chlorpyrifos dosimetry and cholinesterase inhibition. Journal of Toxicology and Environmental Health A, 74, 1334–1350.
134. Leung HW, 1991. Development and Utilization of Physiologically Based Pharmacokinetic Models for Toxicological Applications. Journal of Toxicology and Environmental Health, 32, 247–267.
135. Li J, Wang S, Wang M, Shi W, Du X and Sun C, 2013a. The toxicity of 3-chloropropane-1, 2-dipalmitate in Wistar rats and a metabonomics analysis of rat urine by ultra-performance liquid chromatography-mass spectrometry. Chemico-Biological Interactions, 206, 337–345.
136. Li F, Pang XY, Krausz KW, Jiang CT, Chen C, Cook JA, Krishna MC, Mitchell JB, Gonzalez FJ and Patterson AD, 2013b. Stable Isotope- and Mass Spectrometry-based Metabolomics as Tools in Drug Metabolism: A Study Expanding Tempol Pharmacology. Journal of Proteome Research, 12, 1369–1376.
137. Lieschke GJ and Currie PD, 2007. Animal models of human disease: zebrafish swim into view. Nature Reviews. Genetics, 8, 353–367.
138. Liu Y, Li Y, Liu K and Shen J, 2014. Exposing to cadmium stress cause profound toxic effect on microbiota of the mice intestinal tract. PloS one, 9(2), e85323.
139. Lo Piparo E, Worth A, Manibusan M, Yang C, Schilter B, Mazzatorta P, Jacobs MN, Steinkellner H and Mohimont L, 2011. Use of computational tools in the field of food safety. Regulatory Toxicology and Pharmacology, 60, 354–362.
140. Loccisano AE, Campbell JL, Andersen ME and Clewell HJ, 2011. Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. Regulatory Toxicology and Pharmacology, 59, 157–175.
141. Loizou G and Hogg A, 2011. MEGen: A Physiologically Based Pharmacokinetic Model Generator. Frontiers in Pharmacology, 2, 56.
142. Lyons MA, Yang RSH, Mayeno AN and Reisfeld B, 2008. Computational toxicology of chloroform: Reverse dosimetry using Bayesian inference, Markov chain Monte Carlo simulation, and human biomonitoring data. Environmental Health Perspectives, 116, 1040–1046.
143. McGettigan PA, 2013. Transcriptomics in the RNA-seq era. Current Opinion in Chemical Biology, 17, 4–11.
144. Martati E, Boersma MG, Spenkelink A, Khadka DB, Punt A and Vervoort J, 2011. Physiologically based biokinetic (PBBK) model for safrole bioactivation and detoxification in rats. Chemical Research in Toxicology, 24, 818–834.
145. Mattes WB, Kamp HG, Fabian E, Herold M, Krennrich G, Looser R, Mellert W, Prokoudine A, Strauss V, van Ravenzwaay B, Walk T, Naraoka H, Omura K, Schuppe-Koistinen I, Nadanaciva S, Bush ED, Moeller N, Ruiz-Noppinger P and Piccoli SP, 2013. Prediction of Clinically Relevant Safety Signals of Nephrotoxicity through Plasma Metabolite Profiling. Biomed Research International. doi: 10.1155/2013/202497
146. Mays C, Benfenati E and Pardoe S, 2012. Use and perceived benefits and barriers of QSAR models for REACH: findings from a questionnaire to stakeholders. Chemistry Central Journal, 6. doi: 10.1186/1752-153x-6-159
147. Meek ME, Boobis AR, Crofton KM, Heinemeyer G, Van Raaij M and Vickers C, 2011. Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. Regulatory Toxicology and Pharmacology, 60, S1–S14.
148. Meek ME, Boobis A, Cote I, Dellarco V, Fotakis G, Munn S, Seed J and Vickers C, 2013. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. Journal of Applied Toxicology, 34, 1–18.
149. Meganathan K, Jagtap S, Wagh V, Winkler J, Gaspar JA, Hildebrand D, Trusch M, Lehmann K, Hescheler J, Schluter H and Sachinidis A, 2012. Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells. PLoS One, 7, e44228.
150. Meng Z and Veenstra TD, 2011. Targeted mass spectrometry approaches for protein biomarker verification. Journal of Proteomics, 74, 2650–2659.
151. Menni C, Zhai GJ, MacGregor A, Prehn C, Romisch-Margl W, Suhre K, Adamski J, Cassidy A, Illig T, Spector TD and Valdes AM, 2013. Targeted metabolomics profiles are strongly correlated with nutritional patterns in women. Metabolomics, 9, 506–514.
152. Merrick BA and Bruno ME, 2004. Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. Current Opinion in Molecular Therapeutics, 6, 600–607.
153. Metzker ML, 2010. Sequencing technologies - the next generation. Nature Reviews. Genetics, 11, 31–46.
154. Meyer MR, Orschiedt T and Maurer HH, 2013. Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicology Letters, 217, 137–142.
155. Milreu PV, Klein CC, Cottret L, Acuna V, Birmele E, Borassi M, Junot C, Marchetti-Spaccamela A, Marino A, Stougie L, Jourdan F, Crescenzi P, Lacroix V and Sagot MF, 2014. Telling metabolic stories to explore metabolomics data: a case study on the yeast response to cadmium exposure. Bioinformatics, 30, 61–70.
156. Mirfazaelian A, Kim KB, Anand SS, Kim HJ, Tornero-Velez R, Bruckner JV and Fisher JW, 2006. Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat. Toxicological Sciences, 93, 432–442.
157. Mitra P, Audus K, Williams G, Yazdanian M and Galinis D, 2011. A comprehensive study demonstrating that p-glycoprotein function is directly affected by changes in pH: Implications for intestinal pH and effects on drug absorption. Journal of Pharmaceutical Sciences. doi: 10.1002/jps.22596
158. Montoya GA, Strauss V, Fabian E, Kamp H, Mellert W, Walk T, Looser R, Herold M, Krennrich G, Peter E and van Ravenzwaay B, 2014. Mechanistic analysis of metabolomics patterns in rat plasma during administration of direct thyroid hormone synthesis inhibitors or compounds increasing thyroid hormone clearance. Toxicology Letters, 225, 240–251.
159. Nault R, Forgacs AL, Dere E and Zacharewski TR, 2013a. Comparisons of differential gene expression elicited by TCDD, PCB126, βNF, or ICZ in mouse hepatoma Hepa1c1c7 cells and C57BL/6 mouse liver. Toxicology Letters, 223, 52–59.
160. Nault R, Kim S and Zacharewski TR, 2013b. Comparison of TCDD-elicited genome-wide hepatic gene expression in Sprague-Dawley rats and C57BL/6 mice. Toxicology and Applied Pharmacology, 267, 184–191.
161. Nicholson JK, Lindon JC and Holmes E, 1999. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica, 29, 1181–1189.
162. Nicholson JK and Wilson ID, 2003. Understanding ‘global’ systems biology: Metabonomics and the continuum of metabolism. Nature Reviews Drug Discovery, 2, 668–676.
163. Nossol C, Diesing AK, Walk N, Faber-Zuschratter H, Hartig R, Post A, Kluess J, Rothkotter HJ and Kahlert S, 2011. Air-liquid interface cultures enhance the oxygen supply and trigger the structural and functional differentiation of intestinal porcine epithelial cells (IPEC). Histochemistry and Cell Biology, 136, 103–115.
164. st Century: a vision and a strategy. Washington, The National Academies Press.
165. NRC (National Research Council), 2009. Science and Decisions: Advancing Risk Assessment. Washington, The National Academies Press.
166. NTP (National Toxicology Program), 2004. A National Toxicology Program for the 21st Century: Roadmap to Achieve the NTP Vision Durham: National Institute of Environmental Health Sciences. ntp.niehs.nih.gov/NTP/About_NTP/NTPVision/NTPRoadmap_508.pdf
167. Nuwaysir EF, Bittner M, Trent J, Barrett JC and Afshari CA, 1999. Microarrays and toxicology: The advent of toxicogenomics. Molecular Carcinogenesis, 24, 153–159.
168. OECD (Organisation for Economic Co-operation and Development), 2004. Report from the Expert Group on (Q)SARs on Principles for the Validation of (Q)SARs Series on Testing and Assessment, No. 49. Organisation for Economic Co-Operation and Development, Paris, France. Available online: search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282004%2924&doclanguage=en
169. OECD (Organisation for Economic Co-Operation and Development), 2007. Guidance on Grouping of Chemicals. ENV/JM/MONO(2007)28, Series on Testing and Assessment Number 80, Organisation for Economic Co-Operation and Development, Paris, France. Available online: search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2007)28&doclanguage=en.
170. OECD, 2009a. Report of the second survey on available omics tools. ENV/JM/MONO(2008)35. Series on testing and assessment Number 100. Available online: search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282008%2935&doclanguage=en
171. OECD (Organisation for Economic Co-Operation and Development), 2009b. Guidance document for using the OECD (Q)SAR Application Toolbox to develop chemical categories according to the OECD Guidance on grouping of chemicals. ENV/JM/MONO(2009)5, Series on Testing and Assessment No. 102.
172. OECD (Organisation for Economic Co-Operation and Development), 2011. WHO OECD ILSI/HESI International Workshop on Risk Assessment of Combined Exposures to Multiple Chemicals. Paris, France, OECD Environment Directorate. OECD Environment, Health and Safety Publications. Series on Testing and Assessment. No 108. Available online: search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282011%2910&doclanguage=en
173. OECD (Organisation for Economic Co-Operation and Development), 2012. QSAR toolbox. User Manual. Getting started. Available online: www.oecd.org/chemicalsafety/risk-assessment/TB3%200_GettingStarted_rev2.pdf
174. OECD (Organisation for Economic Co-Operation and Development), 2013. Guidance document on developing and assessing adverse ouctome pathways. Paris, France, OECD Environment Directorate. OECD Environment, Health and Safety Publications. Series on Testing and Assessment. No 184.
175. Oliver S, 2003. Functional genomics: All the king's horses and all the king's men can put humpty together again. Molecular Cell, 12, 1343–1344.
176. Oliver SG, Winson MK, Kell DB and Baganz F, 1998. Systematic functional analysis of the yeast genome. Trends in Biotechnology, 16, 373–378.
177. Ozdemir V, Husereau D, Hyland S, Samper S and Salleh MZ, 2009. Personalized Medicine Beyond Genomics: New Technologies, Global Health Diplomacy and Anticipatory Governance. Current Pharmacogenomics Personalised Medicine, 7, 225–230.
178. Padhi BK, Pelletier G, Williams A, Berndt-Weis L, Yauk C, Bowers WJ and Chu I, 2008. Gene expression profiling in rat cerebellum following in utero and lactational exposure to mixtures of methylmercury, polychlorinated biphenyls and organochlorine pesticides. Toxicology Letters, 176, 93–103.
179. Paini A, Punt A, Scholz G, Gremaud E, Spenkelink B, Alink G, 2012. In vivo validation of DNA adduct formation by estragole in rats predicted by physiologically based biodynamic modelling. Mutagenesis, 27, 653–663.
180. Pan TL, Wang PW, Al-Suwayeh SA, Huang YJ and Fang JY, 2012. Toxicological effects of cationic nanobubbles on the liver and kidneys: biomarkers for predicting the risk. Food and Chemical Toxicology, 50, 3892–3901.
181. Pargent W, Heffner S, Schable KF, Soewarto D, Fuchs H and Hrabe de Angelis M, 2000. MouseNet database: digital management of a large-scale mutagenesis project. Mammalian Genome, 11, 590–593.
182. Patlewicz G, Jeliazkova N, Safford RJ, Worth AP and Aleksiev B, 2008. An evaluation of the implementation of the Cramer classification scheme in the Toxtree software. SAR and QSAR in Environmental Research, 19, 495–524.
183. Patti GJ, Tautenhahn R and Siuzdak G, 2012. Meta-analysis of untargeted metabolomic data from multiple profiling experiments. Nature Protocols, 7, 508–516.
184. Pelekis M and Emond C, 2009. Physiological modeling and derivation of the rat to human toxicokinetic uncertainty factor for the carbamate pesticide aldicarb. Environmental Toxicology and Pharmacology, 28, 179–191.
185. Peng S, Yan L, Zhang J, Wang Z, Tian M and Shen H, 2013. An integrated metabonomics and transcriptomics approach to understanding metabolic pathway disturbance induced by perfluorooctanoic acid. Journal of Pharmacy and Biomedical Analysis, 86, 56–64.
186. Perkins EJ, Ankley GT, Crofton KM, Garcia-Reyero N, LaLone CA, Johnson MS, Tietge JE and Villeneuve DL, 2013. Current perspectives on the use of alternative species in human health and ecological hazard assessments. Environmental Health Perspectives, 121, 1002–1010.
187. Péry AR, Brochot C, Hoet PH, Nemmar A and Bois FY, 2009. Development of a physiologically based kinetic model for 99m-technetium-labelled carbon nanoparticles inhaled by humans. Inhalation Toxicology, 21, 1099–1107.
188. Péry AR, Brochot C, Zeman FA, Mombelli E, Desmots S, Pavan M, Fioravanzo E and Zaldívar JM, 2013. Prediction of dose-hepatotoxic response in humans based on toxicokinetic/toxicodynamic modeling with or without in vivo data: a case study with acetaminophen. Toxicology Letters, 220, 26–34.
189. Peyret T, Poulin P and Krishnan K, 2010. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicology and Applied Pharmacology, 249, 197–207.
190. nd ed.). Hoboken, N.J: Wiley-Blackwell. ISBN 9780470085851.
191. Pielaat A, Barker GC, Hendriksen P, Peijnenburg A and Kuile BH, 2013. A foresight study on emerging technologies: State of the art of omics technologies and potential applications in food and feed safety. REPORT 1: Review on the state of art of omics technologies in risk assessment related to food and feed safety. EFSA supporting publication 2013:EN-495, 126 pp. Available online: www.efsa.europa.eu/publications
192. Pietu G, Mariage-Samson R, Fayein NA, Matingou C, Eveno E, Houlgatte R, Decraene C, Vandenbrouck Y, Tahi F, Devignes MD, Wirkner U, Ansorge W, Cox D, Nagase T, Nomura N and Auffray C, 1999. The Genexpress IMAGE knowledge base of the human brain transcriptome: a prototype integrated resource for functional and computational genomics. Genome Research, 9, 195–209.
193. Poet TS, Kousba AA, Dennison SL and Timchalk C, 2004. Physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus pesticide diazinon. Neurotoxicology, 25, 1013–1130.
194. Potera C, 2014. Clues to Arsenic's Toxicity: Microbiome Alterations in the Mouse Gut. Environmental Health Perspectives, 122, A82.
195. Poulin P and Haddad S, 2013. Hepatocyte composition-based model as a mechanistic tool for predicting the cell suspension: aqueous phase partition coefficient of drugs in in vitro metabolic studies. Journal of Pharmaceutical Sciences, 102, 2806–2818.
196. Price PS, Hollnagel HM and Zabik JM, 2009. Characterizing the Noncancer Toxicity of Mixtures Using Concepts from the TTC and Quantitative Models of Uncertainty in Mixture Toxicity. Risk Analysis, 29, 1534–1548.
197. Punt A, Freidig AP, Delatour T, Scholz G, Boersma MG, Schilter B, van Bladeren PJ and Rietjens IM, 2008. A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat. Toxicology and Applied Pharmacology, 231, 248–259.
198. Punt A, Schiffelers MJWA, Horbach GJ, van De Sandt JJM, Groothuis GMM, Rietjens IMCM and Blaauboer BJ, 2011. Evaluation of research activities and research needs to increase the impact and applicability of alternative testing strategies in risk assessment practice. Regulatory Toxicology and Pharmacology, 61, 105–114.
199. Rabinowitz JR, Goldsmith MR, Little SB and Pasquinelli MA, 2008. Computational molecular modeling for evaluating the toxicity of environmental chemicals: prioritizing bioassay requirements. Environmental Health Perspectives, 116, 573–577.
200. Rakyan VK, Down TA, Balding DJ and Beck S, 2011. Epigenome-wide association studies for common human diseases. Nature Reviews. Genetics, 12, 529–541.
201. Ramirez T, Daneshian M, Kamp H, Bois FY, Clench MR, Coen M, Donley B, Fischer SM, Ekman DR, Fabian E, Guillou C, Heuer J, Hogberg HT, Jungnickel H, Keun HC, Krennrich G, Krupp E, Luch A, Noor F, Peter E, Riefke B, Seymour M, Skinner N, Smirnova L, Verheij E, Wagner S, Hartung T, van Ravenzwaay B and Leist M, 2013. Metabolomics in Toxicology and Preclinical Research. ALTEX-Alternatives to Animal Experimentation, 30, 209–225.
202. Rappaport SM and Smith MT, 2010. Epidemiology. Environment and disease risks. Science, 330, 460–461.
203. Reif DM, Martin MT, Tan SW, Houck KA, Judson RS, Richard AM, Knudsen TB, Dix DJ and Kavlock RJ, 2010. Endocrine profiling and prioritization of environmental chemicals using ToxCast data. Environmental Health Perspectives, 118, 1714–1720.
204. Reif DM, Sypa M, Lock EF, Wright FA, Wilson A, Cathey T, Judson RR and Rusyn I, 2013. ToxPi GUI: an interactive visualization tool for transparent integration of data from diverse sources of evidence. Bioinformatics, 29, 402–403.
205. Reinartz J, Bruyns E, Lin JZ, Burcham T, Brenner S, Bowen B, Kramer M and Woychik R, 2002. Massively parallel signature sequencing (MPSS) as a tool for in-depth quantitative gene expression profiling in all organisms. Briefings in Functional Genomics & Proteomics, 1, 95–104.
206. Robertson DG, Watkins PB and Reily MD, 2011. Metabolomics in Toxicology: Preclinical and Clinical Applications. Toxicological Sciences, 120, S146–S170.
207. Rodriguez-Suarez E and Whetton AD, 2013. The application of quantification techniques in proteomics for biomedical research. Mass Spectrometry Reviews, 32, 1–26.
208. Roncaglioni A, Toropov AA, Toropova AP and Benfenati E, 2013. In silico methods to predict drug toxicity. Current Opinion in Pharmacology, 13, 802–806.
209. Rostami-Hodjegan A and Tucker GT, 2007. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews. Drug Discovery, 6, 140–148.
210. Rostkowski M, Spjuth O and Rydberg P, 2013. WhichCyp: prediction of cytochromes P450 inhibition. Bioinformatics, 29, 2051–2052.
211. Rotroff DM, Wetmore BA, Dix DJ, Ferguson SS, Clewell HJ, Houck KA, 2010. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicological Sciences, 117, 348–358.
212. Rowland M, 2013. Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry. CPT: Pharmacometrics & Systems Pharmacology, 2, e55.
213. Ruiz P, Mumtaz M, Osterloh J, Fisher J and Fowler BA, 2010. Interpreting NHANES biomonitoring data, cadmium. Toxicology Letters, 198, 44–48.
214. Rusyn I and Daston GP, 2010. Computational Toxicology: Realizing the Promise of the Toxicity Testing in the 21st Century. Environmental Health Perspectives, 118, 1047–1050.
215. Sabido E, Selevsek N and Aebersold R, 2012. Mass spectrometry-based proteomics for systems biology. Current Opinion in Biotechnology, 23, 591–597.
216. Santoriello C and Zon LI, 2012. Hooked! Modeling human disease in zebrafish. Journal of Clinical Investigation, 122, 2337–2343.
217. Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, Mitropoulos K, Del Zompo M, and Patrinos GP, 2010. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics, 11, 1149–1167.
218. Sasso AF, Isukapalli SS and Georgopoulos PG, 2010. A generalized physiologically-based toxicokinetic modeling system for chemical mixtures containing metals. Theoretical Biology and Medical Modelling, 7:17.
219. Sasso AF, Georgopoulos PG, Isukapalli SS and Krishnan K, 2012. Bayesian Analysis of a Lipid-Based Physiologically Based Toxicokinetic Model for a Mixture of PCBs in Rats. Journal of Toxicology, 2012, 895391.
220. SCCS (Scientific Committee on Consumer Safety), SCENHIR (Scientific Committee on Emerging and Newly Identified Health Risks) and SCHER (Scientific Committee on Health and Environmental Risks), 2012. Toxicity and Assessment of Chemical Mixtures. 50 pp. Available online:ec.europa.eu/health/scientific_committees/environmental_risks/docs/scher_o_155.pdf
221. Schilter B, Benigni R, Boobis A, Chiodini A, Cockburn A, Cronin MT, Lo Piparo E, Modi S, Thiel A and Worth A, 2014. Establishing the level of safety concern for chemicals in food without the need for toxicity testing. Regulatory Toxicology and Pharmacology, 68, 275–296.
222. Schmidt CW, 2009. TOX 21: new dimensions of toxicity testing. Environmental Health Perspectives, 117(8), A348–353.
223. Schnackenberg LK, Sun JC, Pence LM, Bhattacharyya S, da Costa GG and Beger RD, 2012. Metabolomics evaluation of hydroxyproline as a potential marker of melamine and cyanuric acid nephrotoxicity in male and female Fischer F344 rats. Food and Chemical Toxicology, 50, 3978–3983.
224. Scholz S, 2013. Zebrafish embryos as an alternative model for screening of drug-induced organ toxicity. Archives of Toxicology, 87, 767–769.
225. Scholz S, Sela E, Blaha L, Braunbeck T, Galay-Burgos M, Garcia-Franco M, Guinea J, Kluver N, Schirmer K, Tanneberger K, Tobor-Kaplon M, Witters H, Belanger S, Benfenati E, Creton S, Cronin MT, Eggen RI, Embry M, Ekman D, Gourmelon A, Halder M, Hardy B, Hartung T, Hubesch B, Jungmann D, Lampi MA, Lee L, Leonard M, Kuster E, Lillicrap A, Luckenbach T, Murk AJ, Navas JM, Peijnenburg W, Repetto G, Salinas E, Schuurmann G, Spielmann H, Tollefsen KE, Walter-Rohde S, Whale G, Wheeler JR and Winter MJ, 2013. A European perspective on alternatives to animal testing for environmental hazard identification and risk assessment. Regulatory Toxicology and Pharmacology, 67, 506–530.
226. Setzer RW, Lau C, Mole ML, Copeland MF, Rogers JM and Kavlock RJ, 2001. Toward a biologically based dose-response model for developmental toxicity of 5-fluorouracil in the rat: A mathematical construct. Toxicological Sciences, 59, 49–58.
227. Shi Q, Yang X and Mendrick DL, 2013. Hopes and challenges in using miRNAs as translational biomarkers for drug-induced liver injury. Biomarkers in Medicine, 7, 307–15.
228. Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ and Cho JY, 2013. Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance. Clinical Pharmacology & Therapeutics, 94, 601–609.
229. Shuey DL, Lau C, Logsdon TR, Zucker RM, Elstein KH, Narotsky MG, Setzer RW, Kavlock RJ and Rogers JM, 1994. Biologically-Based Dose-Response Modeling in Developmental Toxicology - Biochemical and Cellular Sequelae of 5-Fluorouracil Exposure in the Developing Rat. Toxicology and Applied Pharmacology, 126, 129–144.
230. Shukla SJ, Huang RL, Austin CP and Xia MH, 2010. The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform. Drug Discovery Today, 15, 997–1007.
231. Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ and Knudsen TB, 2013. Profiling 976 ToxCast Chemicals across 331 Enzymatic and Receptor Signaling Assays. Chemical Research in Toxicology, 26, 878–895.
232. Sjogren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernas H, Abrahamsson B and Tannergren C, 2013. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. European Journal of Pharmacological Sciences, 49, 679–698.
233. Sommer F and Bäckhed F, 2013. The gut microbiota-masters of host development and physiology. Nature Reviews. Microbiology, 11, 227–238.
234. Song L and Florea L, 2013. CLASS: constrained transcript assembly of RNA-seq reads. BMC Bioinformatics, 14 Suppl 5, S14.
235. Steinbeck C, Conesa P, Haug K, Mahendraker T, Williams M, Maguire E, Rocca-Serra P, Sansone SA, Salek RM and Griffin JL, 2012. MetaboLights: towards a new COSMOS of metabolomics data management. Metabolomics, 8, 757–760.
236. Stierum R, Heijne W, Kienhuis A, van Ommen B and Groten J, 2005. Toxicogenomics concepts and applications to study hepatic effects of food additives and chemicals. Toxicology and Applied Pharmacology, 207, 179–188.
237. Sturla SJ, Boobis AR, Fitzgerald RE, Hoeng J, Kavlock RJ, Schirmer K, Whelan M, Wilks MF and Peitsch MC, 2014. Systems toxicology: from basic research to risk assessment. Chemical Research in Toxicology, 27, 314–329.
238. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, Fan TW, Fiehn O, Goodacre R, Griffin JL, Hankemeier T, Hardy N, Harnly J, Higashi R, Kopka J, Lane AN, Lindon JC, Marriott P, Nicholls AW, Reily MD, Thaden JJ and Viant MR, 2007. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics, 3, 211–221.
239. Sun B, Utleg AG, Hu Z, Qin S, Keller A, Lorang C, Gray L, Brightman A, Lee D, Alexander VM, Ranish JA, Moritz RL and Hood L, 2013. Glycocapture-assisted global quantitative proteomics (gagQP) reveals multiorgan responses in serum toxicoproteome. Journal of Proteome Research, 12, 2034–2044.
240. Sun YJ, Wang HP, Liang YJ, Yang L, Li W and Wu YJ, 2012. An NMR-based metabonomic investigation of the subacute effects of melamine in rats. Journal of Proteome Research, 11, 2544–2550.
241. Supic G, Jagodic M and Magic Z, 2013. Epigenetics: a new link between nutrition and cancer. Nutrition and Cancer, 65, 781–792.
242. Sysi-Aho M, Katajamaa M, Yetukuri L and Oresic M, 2007. Normalization method for metabolomics data using optimal selection of multiple internal standards. BMC Bioinformatics, 8. doi: 10.1186/1471-2105-8-93
243. Taylor JA, vom Saal FS, Welshons WV, Drury B, Rottinghaus G, Hunt PA, Toutain PL, Laffont CM and VandeVoort CA, 2011. Similarity of Bisphenol A Pharmacokinetics in Rhesus Monkeys and Mice: Relevance for Human Exposure. Environmental Health Perspectives, 119, 422–430.
244. Teeguarden JG and Barton HA, 2004. Computational modeling of serum-binding proteins and clearance in extrapolations across life stages and species for endocrine active compounds. Risk Analysis, 24, 751–770.
245. Teschendorff AE and Widschwendter M, 2012. Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics, 28, 1487–1494.
246. Thelen K and Dressman JB, 2009. Cytochrome P450-mediated metabolism in the human gut wall. Journal of Pharmacy and Pharmacology, 61, 541–558.
247. Thomas RS, Allen BC, Nong A, Yang L, Bermudez E, Clewell HJ, 3rd and Andersen ME, 2007. A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicological Sciences, 98, 240–248.
248. Thomas RS, Clewell HJ 3rd, Allen BC, Wesselkamper SC, Wang NC, Lambert JC, Hess-Wilson JK, Zhao QJ, Andersen ME, 2011. Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicological Sciences, 120,194–205.
249. Thomas RS, Clewell HJ, Allen BC, Yang LL, Healy E and Andersen ME, 2012. Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: A five chemical case study. Mutation Research-Genetic Toxicology and Environmental Mutagenesis, 746, 135–143.
250. Thomas RS, Wesselkamper SC, Wang NCY, Zhao QJ, Petersen DD, Lambert JC, Cote I, Yang LL, Healy E, Black MB, Clewell HJ, Allen BC and Andersen ME, 2013a. Temporal Concordance between Apical and Transcriptional Points of Departure for Chemical Risk Assessment. Toxicological Sciences, 134, 180–194.
251. Thomas RS, Philbert MA, Auerbach SS, Wetmore BA, Devito MJ, Cote I, Rowlands JC, Whelan MP, Hays SM, Andersen ME, Meek ME, Reiter LW, Lambert JC, Clewell HJ, Stephens ML, Zhao QJ, Wesselkamper SC, Flowers L, Carney EW, Pastoor TP, Petersen DD, Yauk CL and Nong A, 2013b. Incorporating New Technologies Into Toxicity Testing and Risk Assessment: Moving From 21st Century Vision to a Data-Driven Framework. Toxicological Sciences, 136, 4–18.
252. Tice R, 2011. Tox21: Transforming Environmental Health Protection LINCS Consortium Kick-off Meeting, Rockville, USA.
253. Tice RR, Austin CP, Kavlock RJ and Bucher JR, 2013. Improving the Human Hazard Characterization of Chemicals: A Tox21 Update. Environmental Health Perspectives, 121, 756–765.
254. Timchalk C and Poet TS, 2008. Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat. Neurotoxicology, 29, 428–443.
255. Tonnelier A, Coecke S and Zaldivar JM, 2012. Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model. Archives of Toxicology, 86, 393–403.
256. Tornero-Velez R, Mirfazaelian A, Kim KB, Anand SS, Kim HJ, Haines WT, Bruckner JV and Fisher JW, 2010. Evaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model. Toxicology and Applied Pharmacology, 244, 208–217.
257. Truong L, Reif DM, St Mary L, Geier MC, Truong HD and Tanguay RL, 2014. Multidimensional in vivo hazard assessment using zebrafish. Toxicological Sciences, 137, 212–233.
258. Tseng YJ, Hopfinger AJ and Esposito EX. 2012. The great descriptor melting pot: mixing descriptors for the common good of QSAR models. Journal of Computer-Aided Molecular Design, 26,39–43.
259. Turco L, Catone T, Caloni F, Di Consiglio E, Testai E and Stammati A, 2011. Caco-2/TC7 cell line characterization for intestinal absorption: how reliable is this in vitro model for the prediction of the oral dose fraction absorbed in human? Toxicology in Vitro, 25, 13–20.
260. US-EPA (US Environmental Protection Agency). 1996. Proposed guidelines for carcinogen risk assessment. Fed. Reg. 61: 17960–18011.
261. US-EPA (U.S. Environmental Protection Agency), 2002. Science Policy Council. Interim Policy on Genomics. Available online: www.epa.gov/OSP/spc/genomics.pdf
262. US-EPA (U.S. Environmental Protection Agency), 2004. Potential Implications of Genomics for Regulatory and Risk Assessment Applications at EPA. 70pp. Available online: www.epa.gov/osa/pdfs/EPA-Genomics-White-Paper.pdf
263. US EPA (U.S. Environmental Protection Agency). 2005. Guidelines for Carcinogen Risk Assessment. US EPA, Washington, DC. Available at:www.epa.gov/cancerguidelines/
264. US-EPA (U.S. Environmental Protection Agency), 2009. An Effects-based Expert System to Predict Estrogen Receptor Binding Affinity for Food Use Inert Ingredients and Antimicrobial Pesticides: Application in a Prioritization Scheme for Endocrine Disrupting Screening [Draft]. Office of Pesticide Programs, US EPA, Washington, DC. Available at www.regulations.gov/#!documentDetail;D=DPA-HQ-OPP-2009-0322-0002
265. US-EPA (U.S. Environmental Protection Agency), 2013. Next Generation Risk Assessment: Incorporation of Recent Advances in Molecular, Computational, and Systems Biology. Available online: cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=259936#Download
266. Valcke M and Krishnan K, 2014. Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants. Journal of Applied Toxicology, 34(3): 227–240.
267. Van den Berg SJ, Klaus V, Alhusainy W and Rietjens IM, 2013. Matrix-derived combination effect and risk assessment for estragole from basil-containing plant food supplements (PFS). Food and Chemical Toxicology, 62, 32–40.
268. Van der Merwe D, Brooks JD, Gehring R, Baynes RE, Monteiro-Riviere NA and Riviere JE, 2006. A physiologically based pharmacokinetic model of organophosphate dermal absorption. Toxicological Sciences, 89, 188–204.
269. Van Ravenzwaay B, Herold M, Kamp H, Kapp MD, Fabian E, Looser R, Krennrich G, Mellert W, Prokoudine A, Strauss V, Walk T and Wiemer J, 2012. Metabolomics: a tool for early detection of toxicological effects and an opportunity for biology based grouping of chemicals-from QSAR to QBAR. Mutation Research, 746, 144–150.
270. Van Summeren A, Renes J, van Delft JH, Kleinjans JC and Mariman EC, 2012. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicology in Vitro, 26, 373–385.
271. Vasdev N, Dorff PN, O'Neil JP, Chin FT, Hanrahan S and VanBrocklin HF, 2011. Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino) quinazolines, potential EGFR imaging probes. Bioorganic and Medicinal Chemistry, 19, 2959–2965.
272. Vedani A and Dobler M, 2000. Multi-dimensional QSAR in drug research. Predicting binding affinities, toxicity and pharmacokinetic parameters. Progress in Drug Research, 55, 105–135.
273. Vedani A, Dobler M and Lill MA, 2006. The challenge of predicting drug toxicity in silico. Basic & Clinical Pharmacology & Toxicology, 99, 195–208.
274. Verner MA, Ayotte P, Muckle G, Charbonneau M and Haddad S, 2009. A Physiologically Based Pharmacokinetic Model for the Assessment of Infant Exposure to Persistent Organic Pollutants in Epidemiologic Studies. Environmental Health Perspectives, 117, 481–487.
275. Verner MA, McDougall R and Johanson G, 2012. Using population physiologically based pharmacokinetic modeling to determine optimal sampling times and to interpret biological exposure markers: The example of occupational exposure to styrene. Toxicology Letters, 213, 299–304.
276. Verner MA, McDougall R, Glynn A, Andersen ME, Clewell HJ and Longnecker MP, 2013. Is the Relationship between Prenatal Exposure to PCB-153 and Decreased Birth Weight Attributable to Pharmacokinetics? Environmental Health Perspectives, 121, 1219–1224.
277. Villeneuve D, Volz DC, Embry MR, Ankley GT, Belanger SE, Leonard M, Schirmer K, Tanguay R, Truong L and Wehmas L, 2014. Investigating alternatives to the fish early-life stage test: a strategy for discovering and annotating adverse outcome pathways for early fish development. Environmental Toxicology and Chemistry, 33, 158–169.
278. Vinken M, Landesmann B, Goumenou M, Vinken S, Shah I, Jaeschke H, Willett C, Whelan M and Rogiers V, 2013. Development of an Adverse Outcome Pathway from Drug-Mediated Bile Salt Export Pump Inhibition to Cholestatic Liver Injury. Toxicological Sciences, 136, 97–106.
279. Wang Z, Gerstein M and Snyder M, 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nature Review Genetics, 10, 57–63.
280. Washburn MP, Ulaszek RR and Yates JR 3rd, 2003. Reproducibility of quantitative proteomic analyses of complex biological mixtures by multidimensional protein identification technology. Analytical Chemistry, 75, 5054–5061.
281. West PR, Weir AM, Smith AM, Donley ELR and Cezar GG, 2010. Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicology and Applied Pharmacology, 247, 18–27.
282. Wetmore BA, Wambaugh JF, Ferguson SS, Sochaski MA, Rotroff DM and Freeman K, 2012. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicological Sciences, 125, 157–174.
283. Wetmore BA, Wambaugh JF, Ferguson SS, Li L, Clewell HJ 3rd, Judson RS, Freeman K, Bao W, Sochaski MA, Chu TM, Black MB, Healy E, Allen B, Andersen ME, Wolfinger RD and Thomas RS, 2013. Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicological Sciences, 132, 327–346.
284. WHO (World Health Organization), 2002. Genomics and World Health: Report of the Advisory Committee on Health research, Geneva.
285. WHO (World Health Organization), 2005. International Programme on Chemical Safety: Chemical-specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/concentration Response Assessment. World Health Organization: Geneva. Available online: www.who.int/ipcs/methods/harmonization/areas/uncertainty/en/index.html.
286. WHO (World Health Organization), 2010. Characterization and application of physiologically based pharmacokinetic models in risk assessment. Available online: www.who.int/ipcs/methods/harmonization/areas/pbpk_models.pdf?ua=1
287. Wiklund S, Johansson E, Sjostrom L, Mellerowicz EJ, Edlund U, Shockcor JP, Gottfries J, Moritz T and Trygg J, 2008. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Analytical Chemistry, 80, 15–122.
288. Wild CP, 2005. Complementing the genome with an “exposome”: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiology, Biomarkers and Prevention, 14, 1847–1850.
289. Wild CP, 2012. The exposome: from concept to utility. International Journal of Epidemiology, 41, 24–32.
290. Wild CP, Scalbert A and Herceg Z, 2013. Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. Environmental Molecular Mutagenesis, 54, 480–499.
291. Wilkins MR, Sanchez JC, Gooley AA, Appel RD, HumpherySmith I, Hochstrasser DF and Williams KL, 1996. Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it. Biotechnology and Genetic Engineering Reviews, 13, 19–50.
292. Williams TD, Mirbahai L and Chipman JK, 2014. The toxicological application of transcriptomics and epigenomics in zebrafish and other teleosts. Briefings in Functional Genomics. doi: 10.1093/bfgp/elt053
293. Wilmes A, Limonciel A, Aschauer L, Moenks K, Bielow C, Leonard MO, Hamon J, Carpi D, Ruzek S, Handler A, Schmal O, Herrgen K, Bellwon P, Burek C, Truisi GL, Hewitt P, Di Consiglio E, Testai E, Blaauboer BJ, Guillou C, Huber CG, Lukas A, Pfaller W, Mueller SO, Bois FY, Dekant W and Jennings P, 2013. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. Journal of Proteomics, 79, 180–194.
294. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, Bouatra S, Sinelnikov I, Arndt D, Xia J, Liu P, Yallou F, Bjorndahl T, Perez-Pineiro R, Eisner R, Allen F, Neveu V, Greiner R and Scalbert A, 2013. HMDB 3.0 - The Human Metabolome Database in 2013. Nucleic Acids Research, 41, D801–807.
295. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K, Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan GE, Macinnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner R, Li L, Marrie T, Sykes BD, Vogel HJ and Querengesser L, 2007. HMDB: the Human Metabolome Database. Nucleic Acids Research, 35, D521–526.
296. Worth A, Fuart-Gatnik M, Lapenna S, Lo Piparo E, Mostrag-Szlichtyng A and Serafimova R, 2011. The use of computational methods in the toxicological assessment of chemicals in food: current status and future prospects. JRC report EUR 24748 EN. Publications Office of the European Union, Luxembourg. Available online: ihcp.jrc.ec.europa.eu/our_labs/computational_toxicology/publications/
297. Wu BJ, Dong D, Hu M and Zhang SX, 2013. Quantitative Prediction of Glucuronidation in Humans Using the In Vitro-In Vivo Extrapolation Approach. Current Topics in Medicinal Chemistry, 13, 1343–1352.
298. Wu SD, Blackburn K, Amburgey J, Jaworska J and Federle T, 2010. A framework for using structural, reactivity, metabolic and physicochemical similarity to evaluate the suitability of analogs for SAR-based toxicological assessments. Regulatory Toxicology and Pharmacology, 56, 67–81.
299. Xie G, Zheng X, Qi X, Cao Y, Chi Y, Su M, Ni Y, Qiu Y, Liu Y, Li H, Zhao A and Jia W, 2010. Metabonomic evaluation of melamine-induced acute renal toxicity in rats. Journal of Proteome Research, 9, 125–133.
300. Yeo KR, Kenny JR and Rostami-Hodjegan A, 2013. Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. European Journal of Clinical Pharmacology, 69, 1311–1320.
301. Yokoi T and Nakajima M, 2013. microRNAs as mediators of drug toxicity. Annual Review of Pharmacology and Toxicology, 53, 377–400.
302. Yoon M, Campbell JL, Andersen ME and Clewell HJ, 2012. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Critical Reviews in Toxicology, 42, 633–652.
303. Yoon M, Efremenko A, Blaauboer BJ and Clewell HJ, 2014. Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. Toxicology In Vitro, 28, 164–170.
304. Young JF, Luecke RH and Doerge DR, 2007. Physiologically based pharmacokinetic/pharmacodynamic model for acrylamide and its metabolites in mice, rats, and humans. Chemical Research in Toxicology, 20, 388–399.
305. Yu LR, 2011. Pharmacoproteomics and toxicoproteomics: The field of dreams. Journal of Proteomics, 74, 2549–2553.
306. Zaldivar Comenges JM, Menecozzi M, Macko P, Rodriguez R, Bouhifd M and Baraibar Fentanes J, 2011. A Biology-Based Dynamic Approach for the Modelling of Toxicity in Cell Assays: Part II: Models for Cell Population Growth and Toxicity. JRC Scientific and Technical Report EUR 24898 EN. Publications Office of the European Union, Luxembourg. Available from: publications.jrc.ec.europa.eu/repository/.
307. Zaldívar JM, Mennecozzi M, Marcelino Rodrigues R and Bouhifd M, 2010. A biology-based dynamic approach for the modelling of toxicity in cell-based assays. Part I: Fate modelling. EUR 24374 EN.
308. Zhang X, Tsang AM, Okino MS, Power FW, Knaak JB, Harrison LS and Dary CC, 2007. A physiologically based pharmacokinetic/pharmacodynamic model for carbofuran in Sprague-Dawley rats using the exposure-related dose estimating model. Toxicological Sciences, 100, 345–359.
309. Zhu H, Martin TM, Young DM and Tropsha A, 2009. Combinatorial QSAR Modeling of Rat Acute Toxicity by Oral Exposure. Chemical Research in Toxicology, 22, 1913–1921.
310. Zhu XW, Sedykh A, Zhu H, Liu SS and Tropsha A, 2013. The Use of Pseudo-Equilibrium Constant Affords Improved QSAR Models of Human Plasma Protein Binding. Pharmaceutical Research, 30, 1790–1798.